Clene's Amyotrophic Lateral Sclerosis Candidate Shows Favorable Impact On Disease ProgressionBenzinga • 12/01/21
Does Clene Inc. (CLNN) Have the Potential to Rally 238% as Wall Street Analysts Expect?Zacks Investment Research • 11/16/21
Clene Announces Completion of Patient Enrollment in the HEALEY ALS Platform TrialGlobeNewsWire • 11/15/21
Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral SclerosisGlobeNewsWire • 09/23/21
Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021GlobeNewsWire • 09/17/21
Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021GlobeNewsWire • 09/09/21
Clene's Stock Gain As Its Nanotherapeutic Improves Energy Production, Brain Utilization In Patients With Parkinson's, Multiple SclerosisBenzinga • 08/05/21
Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson's Disease and Multiple SclerosisGlobeNewsWire • 08/05/21
Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with AgingGlobeNewsWire • 05/17/21
Clene Nanomedicine Presents Updated Blinded Efficacy Data from Ongoing Phase 2 RESCUE-ALS Study at the ENCALS 2021 Annual MeetingGlobeNewsWire • 05/12/21
Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic TechnologyGlobeNewsWire • 04/30/21
Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference and Launch of Clene Spotlight Webpage on M Vest LLCGlobeNewsWire • 03/10/21
Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform TrialGlobeNewsWire • 03/09/21
Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis StudiesBenzinga • 02/25/21
